Letter to the editor regarding 'A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients'
- PMID: 36636996
- PMCID: PMC9848296
- DOI: 10.1080/0886022X.2022.2153065
Letter to the editor regarding 'A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients'
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Comment on
-
A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients.Ren Fail. 2022 Dec;44(1):94-102. doi: 10.1080/0886022X.2021.2021237. Ren Fail. 2022. PMID: 35156909 Free PMC article.
References
-
- Lu M, Cohen MH, Rieves D, et al. . FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315–319. - PubMed
-
- Singh A, Patel T, Hertel J, et al. . Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907–915. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical